Search for: "Bristol Myers Squibb" Results 101 - 120 of 863
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 Sep 2021, 6:36 pm by Lawrence B. Ebert
Patent No. 6,967,208 (“the ’208 patent”): (1) “substituted with [N] R,” see Bristol-Myers Squibb Co. v. [read post]
25 Apr 2017, 11:56 am by Andrew Hamm
The transcript in Bristol-Myers Squibb Co. v. [read post]
3 Aug 2012, 7:57 am by By PETER J. HENNING
According to a complaint filed by the Securities and Exchange Commission, an employee of Bristol-Myers Squibb did little to cover his tracks when he engaged in an insider trading scheme that generated over $300,000 in profits. [read post]
3 Aug 2012, 7:57 am by By PETER J. HENNING
According to a complaint filed by the Securities and Exchange Commission, an employee of Bristol-Myers Squibb did little to cover his tracks when he engaged in an insider trading scheme that generated over $300,000 in profits. [read post]
15 Feb 2008, 6:19 am
  It is marketed by Bristol Myers Squibb and is a potent antiplatelet agent used for coronary arterial disease and other vascular diseases. [read post]
16 Jan 2012, 7:39 am by Tom Huddleston Jr.
., in its sale to Bristol-Myers Squibb for $2.5 billion--a 163 percent premium over Inhibitex's January 6 closing price. [read post]
1 Oct 2018, 2:24 am by tortsprof
The drug was brought into the U.S. market by Otsuka America and Bristol-Myers Squibb in 2002.... [read post]
29 Jan 2007, 3:58 am
Buying Bristol-Myers, which has a market value [...] [read post]
8 Apr 2008, 2:21 am
On the subject of universities suing commercial players for patent infringement, Repligen and the University of Michigan sued Bristol-Myers Squibb in federal court back in 2006, based on a patent owned by the University of Michigan and the U.S. [read post]
1 Feb 2021, 11:24 am by Timothy Misner
Last month, the Supreme Court denied certiorari in a case that would determine whether the Court’s 2017 decision in Bristol-Myers Squibb Co. v. [read post]
(“Sawai”) to suspend the manufacture and sale of Sawai’s pharmaceutical product (“Sawai’s Product”) developed and sold as a generic drug of Bristol-Myers Squibb (“BMS”)’s cancer drug “Sprycel®” (Case No. 2023 (Yo) 30214; AIK represented BMS in this case). [read post]
28 Feb 2010, 3:17 pm by Christopher T. Hurley
The Food and Drug Administration says, “an organ transplant drug from Bristol-Myers Squibb improves kidney function, but the agency has concerns about potentially fatal side effects. [read post]
27 Jan 2010, 9:04 pm by Patent Docs
District Court for the District of Delaware has ruled that Bristol-Myers Squibb may proceed with its patent infringement suit against defendants Mylan Pharmaceuticals and Matrix Laboratories over Bristol-Myers' patent covering the HIV treatment Sustiva®, U.S. [read post]
8 Aug 2006, 9:34 am
Apotex is currently in patent litigation with Bristol-Myers Squibb and sanofi-aventis over its generic Plavix. [read post]
9 Feb 2010, 7:59 am by David J. Clark
§1832, from his employer Bristol-Myers-Squibb, where he worked from November 2007 through February 2, 2010. [read post]
3 Apr 2014, 9:55 pm by Patent Docs
Bristol-Myers Squibb Company v. [read post]
4 Nov 2017, 9:08 pm by Patent Docs
Strafford will be offering a webcast entitled "Personal Jurisdiction After Bristol-Myers Squibb: Unresolved Issues, Shifting Plaintiff Strategies" on November 7, 2017 from 1:00 to 2:30 pm (EST). [read post]
22 Mar 2015, 9:46 pm by Patent Docs
Bristol-Myers Squibb Co. v. [read post]